RxDoctor Payments DataLook up a doctor →

James George, MD

Gastroenterology · New York, NYNPI 1659380244

Payments from drug & device makers

$375,751in general payments, 2019–2025

Across 2,108 payments — averaging $178.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$146K
  • Janssen Scientific Affairs, LLC$89K
  • AbbVie$87K
  • Takeda Pharmaceuticals U.S.A., Inc.$37K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Bristol Myers Squibb$3K
  • plus $10K from 36 others

What the payments were for

  • Consulting fees$9,9753%
  • Speaking & faculty fees$285,53176%
  • Travel & lodging$37,70810%
  • Food & beverage$42,33111%
  • Education$1830%
  • Other$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$375,751 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$140,192
Medicare patients
109
Services billed
5,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab73$1,904,460
XifaxanRifaximin15$75,391
Humira(Cf) PenAdalimumab11$72,293
Mesalamine13$10,487
Dexlansoprazole DrDexlansoprazole15$5,383
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine52$3,248
Mesalamine ErMesalamine11$3,038
Balsalazide Disodium22$2,884
Pantoprazole Sodium53$877
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$406
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav16$268
Famotidine34$239
Omeprazole31$196
Ondansetron OdtOndansetron11$144
Ciprofloxacin Hcl13$83

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$146,009$1,904,46073 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$3,080$75,39115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →